Navigation Links
OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports
Date:2/15/2008

under the names of Blazer(TM), R stent(TM), Sapphire(TM), Avita(TM), Avita HP(TM), SafeCut(TM), Lumina(TM) and Saffron.

A global company, OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; Tokyo; and Shenzhen, China. OrbusNeich, which has provided cardiology devices to physicians through its predecessor companies since 1979, today supplies products to interventional cardiologists in more than 60 countries. For more information, visit http://www.OrbusNeich.com.

Global Media Contact:

David Schull

Russo Partners LLC

+1 212-845-4271 (office)

+1 858-717-2310 (mobile)

david.schull@russopartnersllc.com


'/>"/>
SOURCE OrbusNeich
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
2. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
3. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
4. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
5. UPDATE: Free CME-certified Webcast: Opening the Door to Better Myocardial Infarction Outcomes: Emergency Departments Hold the Key
6. Free CME-certified Webcast: Opening the Door to Better Myocardial Infarction Outcomes: Emergency Departments Hold the Key
7. Ranexa(R) Added to New ACC/AHA Guidelines on Unstable Angina/Non ST-Elevation Myocardial Infarction (UA/NSTEMI)
8. Melanoma Research Foundation and Seattle Cancer Care Alliance Host Educational Symposium and Reception for Melanoma Patients, Family Members and Healthcare Providers
9. Data from Two Pivotal Trials of AMRIX, a New Once-Daily Extended-Release Muscle Relaxant, Presented at the American Academy of Pain Medicine Meeting
10. Logical Therapeutics Co-Founder and CEO Honored with a Distinguished Investigator Award from the American College of Critical Care Medicine
11. ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... and SHANGHAI , Aug. ... biopharmaceutical company developing next-generation antibiotics, today announced positive ... study for its lead drug candidate MRX-I. MRX-I ... drug-resistant bacteria such as MRSA and VRE, while ... tolerated therapeutic option than currently available oxazolidinone agents. ...
(Date:8/31/2015)... STOCKHOLM , Aug. 31, 2015 Trimb ... an agreement to acquire YouMedical Group BV ("YouMedical"), a ... YouMedical has total annual sales of approximately EUR 16 ... categories. "Our ambition is to build ... an important step toward that goal. YouMedical gives us ...
(Date:8/31/2015)... ... August 31, 2015 , ... There’s a new treatment option ... the first commercially available new FDA approved system in the last 14 years, and ... the high Amenorrhea (zero bleeding) rate of 66%, the high Patient Satisfaction rate of ...
(Date:8/28/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/zsgg5n/global_and_usa ... & USA BioSimilar Market Analysis to 2021" report ... Biosimilar market will be initiated in September as Sandoz ... the global market react? Will biosimilars explode into the ... the US economy up to $250 billion within the ...
Breaking Biology Technology:MicuRX Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections 2U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3Global & USA BioSimilar Market Analysis Report 2015-2021 2Global & USA BioSimilar Market Analysis Report 2015-2021 3
... that Programs to Curb Unsafe Sex and Drug, ... Global AIDS Response, MEXICO CITY, Aug. 5 ... AIDS experts calls on global leaders to aggressively,expand HIV ... and drug use. Citing hundreds of clinical trials and,observational ...
... Quarter 2007, EMERYVILLE, Calif., Aug. 5 Onyx,Pharmaceuticals, ... results,for the three and six months ended June 30, ... per diluted share, for the second quarter of 2008,compared ... per diluted share, in the,same period in 2007. Excluding ...
... ... - Net Loss Continued to Narrow - ... Company Updates 2008 Guidance - ... Health,Inc. (Nasdaq: GHDX ) today reported financial results and business progress,for the quarter ended June 30, 2008., ...
Cached Biology Technology:Leading AIDS Experts Urge Greater Focus on Behavior-Change Programs to Prevent HIV 2Leading AIDS Experts Urge Greater Focus on Behavior-Change Programs to Prevent HIV 3Leading AIDS Experts Urge Greater Focus on Behavior-Change Programs to Prevent HIV 4Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 2Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 3Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 4Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 5Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 6Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 7Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 8Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 9Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 10Genomic Health Announces Second Quarter 2008 Financial Results and Business Progress 2Genomic Health Announces Second Quarter 2008 Financial Results and Business Progress 3Genomic Health Announces Second Quarter 2008 Financial Results and Business Progress 4Genomic Health Announces Second Quarter 2008 Financial Results and Business Progress 5Genomic Health Announces Second Quarter 2008 Financial Results and Business Progress 6Genomic Health Announces Second Quarter 2008 Financial Results and Business Progress 7Genomic Health Announces Second Quarter 2008 Financial Results and Business Progress 8Genomic Health Announces Second Quarter 2008 Financial Results and Business Progress 9Genomic Health Announces Second Quarter 2008 Financial Results and Business Progress 10
(Date:8/6/2015)... REDWOOD CITY, Calif. , Aug. 6, 2015 ... (D-Silicon Valley) will visit Crossmatch ™ to ... secure networks and protect data. Crossmatch is a ... solutions whose technologies and expertise are helping federal ... operational efficiency and security.   "The ...
(Date:8/5/2015)... ALBANY, New York , August 5, 2015 /PRNewswire/ ... new market report titled "Facial Recognition Market - Global ... - 2022", the global market for facial recognition is ... market is driven by increased demand for surveillance systems ... to the rising number of crimes and terrorist activities ...
(Date:8/3/2015)... , Aug. 3, 2015 Synaptics, Inc. ... interface solutions, today announced that members of the executive ... the Pacific Crest Global Technology Leadership Forum on Tuesday, ... conference will be held at the Sonnenalp Resort in ... The presentation may include forward-looking information. An audio webcast ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6
... the regulation of blood stem cells and the complex, ... published in the February issue of Developmental Cell expands ... the role of a key gene known to be ... research will be useful for future studies aimed at ...
... team using a novel genetic cloning and sequencing technique has ... Midwest therapy pool, pointing to the need for closer scrutiny ... by Washington University in St. Louis and involving the University ... new study assessed the microbe population in a warm hospital ...
... studying how external information gets transmitted from outside of ... particular responses. But cell signaling networks are so complex ... , Now, a research team from Stanford, MIT and ... signaling networks quickly and accurately. Their findings appear in ...
Cached Biology News:New insight into regulation of blood stem cells 2New lab technique identifies high levels of pathogens in therapy pool 2New lab technique identifies high levels of pathogens in therapy pool 3Computational Method Speeds Mapping of Cell Signaling Networks 2Computational Method Speeds Mapping of Cell Signaling Networks 3
...
...
...
D.R. Harper and C. Grose (1994) • Includes: virus structure & replication, fundamental virology, immunology and pathogenesis, vaccines and antiviral drugs, novel diagnostic techniques, cloning a...
Biology Products: